Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells 12,000 Shares of Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Catalyst Pharmaceuticals Trading Down 1.2 %

NASDAQ CPRX traded down $0.27 during mid-day trading on Friday, hitting $22.07. The company’s stock had a trading volume of 554,323 shares, compared to its average volume of 1,187,151. The company’s 50 day simple moving average is $21.23 and its 200 day simple moving average is $18.72. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.00 and a twelve month high of $24.27. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 3.44 and a beta of 0.75.

Institutional Trading of Catalyst Pharmaceuticals

Several hedge funds have recently bought and sold shares of CPRX. Vanguard Group Inc. grew its position in Catalyst Pharmaceuticals by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after purchasing an additional 860,244 shares during the period. American International Group Inc. grew its position in Catalyst Pharmaceuticals by 10.0% in the 1st quarter. American International Group Inc. now owns 60,087 shares of the biopharmaceutical company’s stock valued at $958,000 after purchasing an additional 5,463 shares during the period. Lazard Asset Management LLC grew its position in Catalyst Pharmaceuticals by 36.6% in the 1st quarter. Lazard Asset Management LLC now owns 30,334 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 8,133 shares during the period. Price T Rowe Associates Inc. MD grew its position in Catalyst Pharmaceuticals by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock valued at $19,439,000 after purchasing an additional 22,860 shares during the period. Finally, California State Teachers Retirement System grew its position in Catalyst Pharmaceuticals by 4.3% in the 1st quarter. California State Teachers Retirement System now owns 106,357 shares of the biopharmaceutical company’s stock valued at $1,695,000 after purchasing an additional 4,346 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on CPRX shares. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Citigroup raised their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.